相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
The inflammatory microenvironment and microbiome in prostate cancer development
Karen S. Sfanos et al.
NATURE REVIEWS UROLOGY (2018)
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Max D. Wellenstein et al.
IMMUNITY (2018)
Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer
Harsimar B. Kaur et al.
MODERN PATHOLOGY (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili et al.
NATURE REVIEWS UROLOGY (2018)
InForm software: a semi-automated research tool to identify presumptive human hepatic progenitor cells, and other histological features of pathological significance
Anne S. Kramer et al.
SCIENTIFIC REPORTS (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PTEN-L promotes type I interferon responses and antiviral immunity
Yuanyuan Cao et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy
Timea Balatoni et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
IDO1: An important immunotherapy target in cancer treatment
Fangxuan Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Di Zhao et al.
NATURE (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
The tumor suppressor PTEN has a critical role in antiviral innate immunity
Shun Li et al.
NATURE IMMUNOLOGY (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
Valerio Nardone et al.
CANCER BIOLOGY & THERAPY (2016)
In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
C. G. Picanco-Albuquerque et al.
VIRCHOWS ARCHIV (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Valentina Cappello et al.
SCIENTIFIC REPORTS (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
Dean A. Troyer et al.
PROSTATE (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells
Terry-Ann Curran et al.
IMMUNOBIOLOGY (2014)
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
Prabhakar Mithal et al.
INTERNATIONAL JOURNAL OF UROLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade
Maisa Yoshimoto et al.
MODERN PATHOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Timothy J. Wilt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan et al.
CLINICAL CANCER RESEARCH (2011)
PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB-Cytokine Network
Haoqiang Ying et al.
CANCER DISCOVERY (2011)
Intratumoral Forkhead Box P3-Positive Regulatory T Cells Predict Poor Survival in Cyclooxygenase-2 Positive Uveal Melanoma
Dimitrios Mougiakakos et al.
CANCER (2010)
Prostate cancer genomic signature offers prognostic value
Sarah M. Troutman et al.
CANCER BIOLOGY & THERAPY (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
分享论文
